Efficacy And Safety Of Indacaterol 75 G Once Daily In Patients With Moderate-To-Severe COPD

被引：0
|
作者：
Kerwin, E. M.
Meli, J.
Peckitt, C.
Lassen, C.
Kramer, B.
Filcek, S.
机构：
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2011年 / 183卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1595
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of indacaterol 75 μg once daily in patients with moderate-to-severe COPD: pooled analysis of two phase III trials..
    Donohue, James F.
    Siler, Thomas
    Kerwin, Edward M.
    Williams, James
    Kianifard, Farid
    McBryan, Danny
    PHARMACOTHERAPY, 2012, 32 (10): : E242 - E243
  • [2] Indacaterol 75 μg once daily improves health status in patients with moderate-to-severe COPD: responder analysis
    Mahler, Donald A.
    Dunn, Leonard J.
    Gotfried, Mark H.
    Williams, James
    Lawrence, David
    McBryan, Danny
    PHARMACOTHERAPY, 2012, 32 (10): : E242 - E242
  • [3] Once-daily indacaterol 75 μg in moderate-to-severe COPD: results of a Phase IV study assessing time until patients' perceived onset of effect
    Siler, Thomas M.
    LaForce, Craig F.
    Kianifard, Farid
    Williams, James
    Spangenthal, Selwyn
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2014, 9 : 1 - 7
  • [4] EFFICACY AND SAFETY OF ONCE-DAILY INDACATEROL/MOMETASONE COMPARED WITH TWICE-DAILY SALMETEROL/FLUTICASONE IN PATIENTS WITH MODERATE TO VERY SEVERE COPD
    Kirsten, Anne-Maria
    Richard, Alexia
    Tanase, Ana-Maria
    Cao Weihua
    Hosoe, Motoi
    Hederer, Bettina
    THORAX, 2014, 69 : A187 - A187
  • [5] Safety Of Indacaterol/glycopyrrolate 27.5/15.6 μg Twice Daily In Patients With Moderate-To-Severe COPD: Analysis From The Flight Studies
    Ferguson, G. T.
    Donohue, J. F.
    Fucile, S.
    Yadao, A.
    Maitra, S.
    Ayers, T.
    Fogel, R.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [6] Safety Profile of Glycopyrronium Compared With Once-Daily Indacaterol in Patients With COPD With Moderate-to-Severe Airflow Limitation: The GEM3 Study
    Mahler, Donald
    Gifford, Alex
    Satti, Aditi
    Jessop, Nicola
    Eckert, Joerg H.
    D'Andrea, Peter
    Banerjee, Rudrani
    CHEST, 2015, 148 (04)
  • [7] Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data
    Bleecker, Eugene R.
    Siler, Thomas
    Owen, Roger
    Kramer, Benjamin
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2011, 6 : 431 - 438
  • [8] Safety and Efficacy of 12-Week or Longer Indacaterol Treatment in Moderate-to-Severe COPD Patients: A Systematic Review
    Jiang, Fa-Ming
    Liang, Zong-An
    Zheng, Qiao-Ling
    Wang, Rong-Chun
    Luo, Jian
    Li, Chun-Tao
    LUNG, 2013, 191 (02) : 135 - 146
  • [9] Safety and Efficacy of 12-Week or Longer Indacaterol Treatment in Moderate-to-Severe COPD Patients: A Systematic Review
    Fa-Ming Jiang
    Zong-An Liang
    Qiao-Ling Zheng
    Rong-Chun Wang
    Jian Luo
    Chun-Tao Li
    Lung, 2013, 191 : 135 - 146
  • [10] Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
    Anthony D'Urzo
    Gary T Ferguson
    Jan A van Noord
    Kazuto Hirata
    Carmen Martin
    Rachael Horton
    Yimeng Lu
    Donald Banerji
    Tim Overend
    Respiratory Research, 12
12345